Table 3.
Examples of the impact of PCCL 4 on remuneration for oncologic DRGs with conservative treatment such as chemotherapy(base rate EUR 2,950.00)
| DRG | PCCL 0–3 | PCCL 4 |
|---|---|---|
| (remuneration, EUR) | (remuneration, EUR) | |
| B66 brain cancer | B66D (2,107.00) | B66B (3,757.00) |
| D60 ENT cancer | D60C (1,767.00) | D60B (2,184.00) |
| E71 thorax cancer | E71B (1,714.00) | E71A (3,322.00) |
| G60 GI cancer | G60B (1,162.00) | G60A (1,911.00) |
| H61 pancreas cancer | H61B (1,914.00) | H61A (3,369.00) |
| I65 soft tissue cancer | I65C (2,322.00) | I65B (3,337.00) |
| J62 breast cancer | J62B (1,702.00) | J62A (3,349.00) |
| L62 genitourinary cancer | L62B (1,576.00) | L62A (3,273.00) |
| M60 cancer of the male genitals | M60C (1,644.00) | M60A (3,493.00) |
| N60 cancer of the female genitals | N60B (1,661.00) | N60A (3956.00) |
ENT = Ear nose throat; GI = gastrointestinal.